JAZZ
Price
$113.86
Change
-$0.77 (-0.67%)
Updated
Aug 1, 10:40 AM (EDT)
Capitalization
6.94B
4 days until earnings call
PBM
Price
$4.30
Change
-$0.73 (-14.51%)
Updated
Aug 1, 10:48 AM (EDT)
Capitalization
3.61M
Interact to see
Advertisement

JAZZ vs PBM

Header iconJAZZ vs PBM Comparison
Open Charts JAZZ vs PBMBanner chart's image
Jazz Pharmaceuticals
Price$113.86
Change-$0.77 (-0.67%)
Volume$300
Capitalization6.94B
Psyence Biomedical
Price$4.30
Change-$0.73 (-14.51%)
Volume$586
Capitalization3.61M
JAZZ vs PBM Comparison Chart in %
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. PBM commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and PBM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (JAZZ: $114.63 vs. PBM: $5.07)
Brand notoriety: JAZZ and PBM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 76% vs. PBM: 4112%
Market capitalization -- JAZZ: $6.94B vs. PBM: $3.61M
JAZZ [@Biotechnology] is valued at $6.94B. PBM’s [@Biotechnology] market capitalization is $3.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $223.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whilePBM’s FA Score has 1 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • PBM’s FA Score: 1 green, 4 red.
According to our system of comparison, PBM is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 5 TA indicator(s) are bullish while PBM’s TA Score has 3 bullish TA indicator(s).

  • JAZZ’s TA Score: 5 bullish, 4 bearish.
  • PBM’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than PBM.

Price Growth

JAZZ (@Biotechnology) experienced а -2.86% price change this week, while PBM (@Biotechnology) price change was -49.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.13%. For the same industry, the average monthly price growth was +16.53%, and the average quarterly price growth was +40.85%.

Reported Earning Dates

JAZZ is expected to report earnings on Nov 05, 2025.

PBM is expected to report earnings on Jun 25, 2025.

Industries' Descriptions

@Biotechnology (-1.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAZZ($6.94B) has a higher market cap than PBM($3.61M). JAZZ has higher P/E ratio than PBM: JAZZ (15.57) vs PBM (0.12). JAZZ YTD gains are higher at: -6.918 vs. PBM (-69.866). JAZZ has higher annual earnings (EBITDA): 1.25B vs. PBM (-46.56M). JAZZ has more cash in the bank: 2.57B vs. PBM (1.93M). PBM has less debt than JAZZ: PBM (2.5M) vs JAZZ (5.42B). JAZZ has higher revenues than PBM: JAZZ (4.07B) vs PBM (0).
JAZZPBMJAZZ / PBM
Capitalization6.94B3.61M191,920%
EBITDA1.25B-46.56M-2,683%
Gain YTD-6.918-69.86610%
P/E Ratio15.570.1212,836%
Revenue4.07B0-
Total Cash2.57B1.93M133,057%
Total Debt5.42B2.5M216,713%
FUNDAMENTALS RATINGS
JAZZ: Fundamental Ratings
JAZZ
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
PROFIT vs RISK RATING
1..100
94
SMR RATING
1..100
61
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
84
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JAZZPBM
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
59%
Bullish Trend 1 day ago
64%
Momentum
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
60%
Bullish Trend 8 days ago
88%
Declines
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIVE15.70-0.03
-0.19%
Live Ventures
SBLK18.26-0.09
-0.49%
Star Bulk Carriers Corp
REG71.39-0.92
-1.27%
Regency Centers Corp
VHI15.70-0.24
-1.51%
Valhi
NBY0.58-0.04
-6.29%
NovaBay Pharmaceuticals

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with AMLX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-1.28%
AMLX - JAZZ
43%
Loosely correlated
+0.88%
FTRE - JAZZ
39%
Loosely correlated
-7.50%
TECH - JAZZ
38%
Loosely correlated
-5.18%
BMRN - JAZZ
38%
Loosely correlated
-0.65%
SYRE - JAZZ
37%
Loosely correlated
-1.85%
More

PBM and

Correlation & Price change

A.I.dvisor tells us that PBM and ATHA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PBM and ATHA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBM
1D Price
Change %
PBM100%
-6.16%
ATHA - PBM
32%
Poorly correlated
+6.44%
SLRX - PBM
28%
Poorly correlated
-23.35%
CRBU - PBM
25%
Poorly correlated
-0.98%
VKTX - PBM
25%
Poorly correlated
-3.38%
JAZZ - PBM
25%
Poorly correlated
-1.28%
More